HIV/AIDS Clinical Trials in Philadelphia

Showing 41-60 of 315 trials

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

NCT02797171

This study will evaluate the safety, pharmacokinetics, and antiviral activity of VRC-HIVMAB060-00-AB (VRC01) and VRC-HIVMAB080-00-AB (VRC01LS) in the serum and mucosa of healthy, HIV-uninfected adults.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)80 participantsStarted Mar 2017

Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States • Seattle, Washington, United States +1 more locations

COMPLETEDPHASE4< 1 mile

B/F/TAF Switch Study for HIV-HBV Coinfection

NCT03797014

The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B. As this is a switch study, all eligible subjects enrolled will be switched from their current antiretroviral regimen to B/F/TAF will be followed on treatment for 48 weeks.

HIV-1-infectionHepatitis B

University of Maryland, Baltimore28 participantsStarted Apr 2019

Baltimore, Maryland, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPHASE4< 1 mile

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777

People infected with HIV often have cognitive dysfunction even if they are on antiretroviral therapy (ART) and have undetectable viral loads. The study evaluated if the addition of maraviroc (MVC) and dolutegravir (DTG) (which are two antiretroviral \[ARV\] medications) to participants' existing ART regimens improved participants' neurocognitive performance.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)191 participantsStarted Apr 2016

Los Angeles, California, United States • San Diego, California, United States • Torrance, California, United States +27 more locations

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

B/F/TAF Switch Study for HIV-HBV Coinfection

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

HIV/AIDS Trials in Other Cities

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Rapid Diagnostics for HIV and Hepatitis

A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

HBV-HIV Coinfection Research Network

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

ID & Testing in Male Partners

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Rectal Microbicide Acceptability, Tolerability and Adherence

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

Other Conditions in Philadelphia